Relationship of Ras association domain family 1 methylation and K-Ras mutation in primary non-small cell lung cancer

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6206-6211

  Kim, Duk Hwan ^a   Kim, Jin Seuk ^a   Park, Jung Ho ^a   Lee, Suk Kyoo ^a   Ji, Yong Ick ^a   Kwon, Young Mi ^a   Shim, Young Mog ^b   Han, Joungho ^b   Park, Joobae ^b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN;

APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; DNA METHYLATION; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; RASSF1A GENE; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CODON; DNA METHYLATION; FEMALE; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 0141954012     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat. Genet., 25: 315-319, 2000.
2. Kuzmin, I. K., Gillespie, J. W., Protopopov, A., Geil, L., Dreijerink, K., Yang, Y., Vocke, C. D., Duh, F-M., Zabarovsky, E., Minna, J. D., Rhim, J. S., Emmert-Buck, M. R., Linehan, W. M., and Lerman, M. I. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res., 62: 3498-3502, 2002.
3. Lo, K-W., Kwong, J., Hui, A. B-Y., Chan, S. Y-Y., To, K-F., Chan, S-C., Chow, L. S-N., Teo, P. M. L., Johnson, P. J., and Huang, D. P. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res., 61: 3877-3881, 2001.
4. Agathanggelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A., Hosoe, S., Lerman, M. I., Minna, J. D., Maher, E. R., and Latif, F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene, 20: 1509-1518, 2001.
5. Lusher, M. E., Lindsey, J. C., Latif, F. L., Pearson, A. D. J., Ellison, D. W., and Clifford, S. C. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res., 62: 5906-5911, 2002.
6. Burbce, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Virmani, A., Bader, Y., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gadzar, A. F., Lerman, M. I., Zabarovsky, E., White, M., and Minna, J. D. The RASSF1A locus in the 3p21.3 homozygous deletion region: epigenetic inactivation in lung and breast cancer and suppression of the malignant phenotype. J. Natl. Cancer Inst. (Bethesda), 93: 691-699, 2001.
7. Dammann, R., Yang, G., and Pfeifer, G. P. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61: 3105-3109, 2001.
8. Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X-F., Seed, B., and Avruch, J. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol., 12: 253-265, 2002.
9. Vavvas, D., Li, X., Avruch, J., and Zhang, X-F. Identification of Norel as a potential ras effector. J. Biol. Chem., 273: 5439-5442, 1998.
10. Lerman, M. I., and Minna, J. D. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res., 60: 6116-6133, 2000.
11. Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J., and Clark, G. J. Ras uses the novel tumor suppressor RASSF1A as an effector to mediate apoptosis. J. Biol. Chem., 275: 35669-35672, 2000.
12. Ortiz-Vega, S., Khokhlatchev, A., Nedwidek, M., Zhang, X., Dammann, R., Pfeifer, G. P., and Avruch, J. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore 1. Oncogene, 21: 1381-1390, 2002.
13. Van Engeland, M., Roemen, G. M. J. M., Brink, M., Paehen, M. M. M., Weijenberg, M. P., de Bruïne, A. P., Arends, J. W., van den Brandts, P. A., de Goeij, A. F. P. M., and Herman, J. P. K-Ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 21: 3792-3795, 2002.
14. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
15. Fukuyama, Y., Mitsudomi, T., Sugio, K., Ishida, T., Akazawa, K., and Sugimachi, K. K-Ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small cell lung cancer. Br. J. Cancer, 75: 1125-1130, 1997.
16. Graziano, S. L., Gamble, G. P., Newman, N. B., Abbott, L. Z., Rooney, M., Mookherjee, S., Lamb, M. L., Kohman, L. J., and Poiesz, B. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small cell lung cancer. J. Clin. Oncol., 17: 668-675, 1999.
17. Gregorio, L. D., Manenti, G., Incarbone, M., Pilotti, S., Pastorino, U., Pierotti, M. A., and Dmgani, T. A. Prognostic value of loss of heterozygosity and kras2 mutations in lung adenocarcinoma. Int. J. Cancer, 79: 269-272, 1999.
18. Tomizawa, Y., Kohno, T., Kondo, H., Otsuka, A., Nishioka, M., Niki, T., Yamada, T., Maeshima, A., Yoshimura, K., Saito, R., Minna, J. D., and Yokota, J. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin. Cancer Res., 8: 2362-2368, 2002.
19. Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., and White, M. A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol., 22: 4309-4318, 2002.
20. Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L., and Conti, C. J. Induction of cyclin D1 overexpression by activated ras. Oncogene, 9: 3627-3633, 1994.
21. Liu, J-J., Chao, J-R., Jiang, M-C., Ng, S-Y., Yen, J. J-Y., and Yang-Yen, H-F. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells. Mol. Cell. Biol., 15: 3654-3663, 1995.
22. Winston, J. T., Coats, S. R., Wang, Y-Z., and Pledger, W. J. Regulation of the cell cycle machinery by oncogenic ras. Oncogene, 12: 127-134, 1996.
23. Kim, S-T., Lim, D-S., Canman, C. E., and Kastan, M. B. Substrate specificities and identification of putative substrates of ATM kinase family members. J. Biol. Chem., 274: 37538-37543, 1999.
24. Feig, L. A., and Buchsbaum, R. J. Cell signaling: life or death decisions of Ras proteins. Curr. Biol., 12: R259-R261, 2002.